VetDC sues Piramal Pharma arm, seeks nearly Rs 75 crore as damages

Published On 2023-12-01 09:00 GMT | Update On 2023-12-02 12:21 GMT

New Delhi: Piramal Pharma Ltd has said VetDC Inc, an erstwhile partner, has filed a civil suit against its wholly-owned arm Piramal Pharma Solutions Inc seeking damages of up to USD 8.91 million (nearly Rs 75 crore) in a court in the US.

Piramal Pharma Solutions Inc (PPS) and VetDC had entered into a supply agreement in 2018 under which PPS manufactured and supplied certain products to VetDC. This agreement expired in December 2021, Piramal Pharma said in a regulatory filing.

"VetDC has initiated a civil suit on November 28, 2023 making certain claims in relation to batches of the product manufactured and supplied during 2018-2019 which were rejected or partially rejected due to contamination," it added.

The suit has been filed before the District Court for the Eastern District of Kentucky, USA.

Further, VetDC also claims that it has suffered losses due to breach of contract.

"VetDC has alleged that it has suffered damages to the extent of USD 8.91 million approximately under various counts in this civil suit. VetDC has sought actual damages, costs expended, pre and post judgment interest and reasonable attorney fees as reliefs in this civil suit," the filing said.

"We believe that VetDC claims are incorrect and/or are without adequate legal basis. PPS will be addressing this civil suit within the designated time," Piramal Pharma said.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

VetDC sues Piramal Pharma arm, seeks nearly Rs 75 crore as damages

Similar News

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations

CDSCO Panel Rejects Theon Pharma's Proposal for Empagliflozin, Linagliptin, Metformin FDC

Virchow Biotech Gets CDSCO Panel Nod for Semaglutide BE, Phase III Trials

Industry needs to come forward, take advantage of funds available for MedTech Sector: DoP Joint Secretary

USFDA inspection: Aurobindo Pharma receives 8 observations for Unit-XII